Drugs / YR001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05718921 | Apr → Aug 2023 | atopic eczema, psoriasis | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06309355 | Jun 2024 → Nov 2025 | atopic eczema | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YR001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05718921 ↗ |
| Route | Topical | “Part A: Single topical dose” NCT05718921 ↗ |